BioSpace News Archive

Migraine is a disabling disease that costs families 70% more in health care expenses than families without a migraine sufferer

-The Centers for Medicare &; Medicaid Services (CMS) announced the SpineJack implantable fracture reduction system qualified for the Transitional Pass-Through (TPT) payment as part of the 2021 Medicare Hospital Outpatient Prospective Payment System.

– Baseline data from the BUTTERFLY observational study provide initial validation of standard measures of cognition (BSID-III and WPPSI-IV) for use in evaluating non-seizure comorbidities in people with Dravet syndrome – – The current design for the ongoing MONARCH Phase 1/2a study to assess both single and multiple ascending doses of STK-001 in children and adolescents with Dravet syndrome will be presented –

Zynx Health® announced that it has significantly expanded and updated the publicly accessible COVID-19 clinical decision support available on its website, zynxhealth.com.

Sarah Cannon to Present Latest in Blood Cancer Research at the 62 nd ASH Annual Meeting & Exposition

The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of the Phase 3 APOLLO study showing that the addition of DARZALEX FASPRO ®

Incyte Announces First Data from REACH3 Trial Showing Ruxolitinib (Jakafi ® ) Significantly Improved Outcomes in Patients with Steroid-Refractory or Steroid-Dependent Chronic Graft-Versus-Host Disease - Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms 1 - Findings from the study are being presented at ASH 2020, and complement previously-reported positive results for Jakafi in

Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced underwritten public offering of 2,000,000 shares by the Company of its Class A common stock, at a price to the public of $140.85 per share, for gross proceeds of $281.7 million. Reata has granted the underwriters a 30-day option to purchase 300,000 additional shares of its Cla

KU Leuven, a leading research institution and one of the top 50 universities in the world and Batavia Biosciences, a contract development and manufacturing organization focused on delivering sustainable manufacturing solutions in the field of vaccines and oncology, today announce their partnership on the development of a vector based COVID-19 vaccine candidate.

Advisory firm Avenue Group® conducted a series of one-on-one, in-depth phone interviews with doctors, nurses, and members of the general public to better understand what needs to happen in order for Americans to feel comfortable choosing to take a COVID-19 vaccine